医学
淋巴瘤
滤泡性淋巴瘤
眼肿瘤
套细胞淋巴瘤
内科学
病理
肿瘤科
作者
Stine Dahl Vest,Sarah E. Coupland,Bita Esmaeli,Paul T. Finger,Gerardo F. Graue,Hans E. Grossniklaus,Tine Gadegaard Hindsø,Frederik Holm,SantoshG Honavar,Jwu Jin Khong,Marina Knudsen Kirkegaard,Penelope McKelvie,Lauge Hjorth Mikkelsen,Kaustubh Mulay,P Rasmussen,Volkert Siersma,Lene Dissing Sjö,Matthew Sniegowski,Bradley A. Thuro,Geeta K. Vemuganti,Steffen Heegaard
标识
DOI:10.1136/bjophthalmol-2021-320466
摘要
To examine whether the specific location of ocular adnexal lymphoma (OAL) and the American Joint Committee on Cancer (AJCC) TNM tumour stage are prognostic factors for mortality in the main OAL subtypes.Clinical and survival data were retrospectively collected from seven international eye cancer centres. All patients from 1980 to 2017 with histologically verified primary or secondary OAL were included. Cox regression was used to compare the ocular adnexal tumour locations on all-cause mortality and disease-specific mortality.OAL was identified in 1168 patients. The most frequent lymphoma subtypes were extranodal marginal zone B-cell lymphoma (EMZL) (n=688, 59%); follicular lymphoma (FL) (n=150, 13%); diffuse large B-cell lymphoma (DLBCL) (n=131, 11%); and mantle cell lymphoma (MCL) (n=89, 8%). AJCC/TNM tumour-stage (T-stage) was significantly associated with disease-specific mortality in primary ocular adnexal EMZL and increased through T-categories from T1 to T3 disease. No associations between AJCC/TNM T-stage and mortality were found in primary ocular adnexal FL, DLBCL, or MCL. EMZL located in the eyelid had a significantly increased disease-specific mortality compared with orbital and conjunctival EMZL, in both primary EMZL and the full EMZL cohort. In DLBCL, eyelid location had a significantly higher disease-specific mortality compared with an orbital or lacrimal gland location.Disease-specific mortality is associated with AJCC/TNM T-stage in primary ocular adnexal EMZL patients. Lymphoma of the eyelid has the highest disease-specific mortality in primary EMZL, and in the full cohort of EMZL and DLBCL patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI